Status:
COMPLETED
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
Lead Sponsor:
Pfizer
Conditions:
Pneumococcal Infections
Eligibility:
All Genders
18-64 years
Phase:
PHASE3
Brief Summary
This study will assess the safety, tolerability and immune response of 13-valent pneumococcal conjugate vaccine (13vPnC) compared with 23-valent Pneumococcal Polysaccharide Vaccine (23vPS). Although t...
Eligibility Criteria
Inclusion
- First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
- Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
- Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.
Exclusion
- Previous immunization with any licensed or experimental pneumococcal vaccine.
- Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
- Known or suspected impairment of immunological function.
Key Trial Info
Start Date :
February 27 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
2141 Patients enrolled
Trial Details
Trial ID
NCT00427895
Start Date
February 27 2007
End Date
August 1 2011
Last Update
November 15 2021
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Accelovance
Huntsville, Alabama, United States, 35802
2
East Valley Family Physicians, PLC
Chandler, Arizona, United States, 85224
3
Clinical Research Advantage/Central Phoenix
Phoenix, Arizona, United States, 85020
4
University Clinical Research, Inc.
Pembroke Pines, Florida, United States, 33024